Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

Mammalian target of rapamycin (mTOR) inhibitors are currently considered an alternative immunosuppressive treatment that can prevent the nephrotoxicity, viral infections and malignancies that are associated with calcineurin inhibitor-based immunosuppressive regimens. However, the side effects of mTO...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatault, Philippe, Lebranchu, Yvon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834549/
https://www.ncbi.nlm.nih.gov/pubmed/24565231
http://dx.doi.org/10.1186/2047-1440-2-S1-S3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834549/
https://www.ncbi.nlm.nih.gov/pubmed/24565231
http://dx.doi.org/10.1186/2047-1440-2-S1-S3

Ejemplares similares